Aethlon Medical, Inc. (AEMD)

NCM – Real Time Price. Currency in USD

2.19

0.00 (0.00%)

At close: May 12, 2026, 4:00 PM EDT

2.24

+0.05 (2.21%)

After-hours: May 12, 2026, 5:21 PM EDT

24.03.2026

Advancements in Novel Immunotherapeutics in The Oncology Battle

Vancouver, Kelowna, and Delta, British Columbia--(Newsfile Corp. - March 24, 2026) - Investorideas.com, a go-to investing platform, releases an industry snapshot looking at advancements in novel immunotherapeutics, featuring Aethlon Medical, Inc. (NASDAQ: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications. Advancements in Novel Immunotherapeutics in The Oncology Battle To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/6292/289695_0e46dab6145c8910_001full.jpg Novel immunotherapeutics have transformed oncology, moving away from broad, non-specific treatments toward highly personalized strategies that harness the patient's immune system to precisely target cancer cells.

24.03.2026

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

SAN DIEGO, March 24, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier®, an extracorporeal device for oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review of the second cohort participant data and recommended advancing to the third and final cohort. They also stated that "no safety concerns were noted with Hemopurifier device/procedure".

12.03.2026

Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities

SAN DIEGO, March 12, 2026 /PRNewswire/ -- Aethlon Medical, Inc. ("Aethlon" or the "Company") (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that it is evaluating a range of strategic opportunities and has engaged Maxim Group LLC ("Maxim") to act as the Company's exclusive financial advisor in connection with this process. The Company engaged Maxim following preliminary inbound interest regarding potential strategic opportunities.

06.03.2026

Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th

The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorConferences.com

23.02.2026

Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

Aethlon invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation on the Emerging Growth Conference. SAN DIEGO, Feb. 23, 2026 /PRNewswire/ -- Aethlon Medical, Inc. (the Company or Aethlon) (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 25, 2026 at 12:30-1:00 PM ET.

19.02.2026

Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript

13.02.2026

Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript

Videos

No Data

There is no data to display

Press releases

24.03.2026

Aethlon Medical, Inc. (AEMD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Aethlon Medical, Inc. (AEMD)

Advancements in Novel Immunotherapeutics in The Oncology Battle

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities

Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th

Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript

Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript

Videos

No Data

Press releases

Advancements in Novel Immunotherapeutics in The Oncology Battle

Advancements in Novel Immunotherapeutics in The Oncology Battle

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities

Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th

Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript

Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript

Videos

No Data

Press releases

Advancements in Novel Immunotherapeutics in The Oncology Battle

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities

Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update

Search stocks

Aethlon Medical, Inc. (AEMD)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Aethlon Medical, Inc. (AEMD)

Advancements in Novel Immunotherapeutics in The Oncology Battle

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities

Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th

Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript

Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript

Videos

No Data

Press releases

Advancements in Novel Immunotherapeutics in The Oncology Battle

Advancements in Novel Immunotherapeutics in The Oncology Battle

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities

Aethlon Medical to Present at the Life Sciences Investor Forum on March 12th

Aethlon Medical to Present on the Emerging Growth Conference on February 25th 2026

Aethlon Medical, Inc. (AEMD) Shareholder/Analyst Call Prepared Remarks Transcript

Aethlon Medical, Inc. (AEMD) Q3 2026 Earnings Call Transcript

Videos

No Data

Press releases

Advancements in Novel Immunotherapeutics in The Oncology Battle

Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review

Aethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities

Aethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update